A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2, Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 255
- Population
- ALL · 50 Years to 89 Years
- Duration
- 2026-04-17 to 2029-03-29
- Intervention
- bispecific anti-VEGF and anti-complement
- Comparator
- Part A: Arm 1; Part B: Arm 1; Part B: Arm 2; Part B: Arm 3; Part B: Arm 4
- Outcomes measured
- Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). — From enrollment to the end of trea…; Part B: Change from baseline in mean BCVA score. — From enrollment followed by injection and assessments visits every 8…; Part A: Change in baseline in mean BCVA score. — From enrollment until week 16; Part A: Change from Baseline in mean central subfield macular thickness (CST). — From enrollment to end of treatment at…; Part B: Mean change from baseline in CST. — From enrollment to Week 36.; Part B: Proportion of participants with greater than or equal to 15-letter improvement in BCVA from baseline. — From en…; Part B: Percent change in CNV lesion size vs aflibercept. — From enrollment to Week 96.; Part B: Change in square root of GA lesion size. — From enrollment to Week 96.
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.